BPG is committed to discovery and dissemination of knowledge
Systematic Reviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 125240
Published online Nov 27, 2026. doi: 10.4254/wjh.125240
Use of N-of-1 trials in liver diseases: A systematic review
Khalid M AlNaamani, Siham AlSinani, Mohamed El-Kassas
Khalid M AlNaamani, Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat 111, Oman
Khalid M AlNaamani, Steatotic Liver Diseases Study Foundation in Middle East and North Africa, Cairo 11795, Al Qāhirah, Egypt
Siham AlSinani, Department of Child Health, Sultan Qaboos University Hospital, University Medical City, Muscat 123, Oman
Mohamed El-Kassas, Department of Endemic Medicine, Capital University (formerly Helwan University), Cairo 11795, Egypt
Author contributions: AlNaamani KM contributed to conceptualization, methodology, investigation, data curation, formal analysis, writing the original draft, review and editing, and supervision; AlSinani S contributed to methodology, investigation, data curation, validation, writing the original draft, review, and editing; El-Kassas M. contributed to methodology, writing the original draft, review and editing, and supervision.
AI contribution statement: No AI tool was used in writing this manuscript.
Conflict-of-interest statement: The Authors declare no conflict of interest in relation to this manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Khalid M AlNaamani, Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat 111, Oman. noumani73@gmail.com
Received: July 2, 2026
Revised: September 1, 2026
Accepted: November 5, 2026
Published online: November 27, 2026
Processing time: 141 Days and 8.2 Hours
Abstract
BACKGROUND

Chronic liver diseases are heterogeneous and include autoimmune, genetic, metabolic, cholestatic, vascular, and idiopathic etiologies. Rare or slowly progressive conditions may make conventional randomized controlled trials difficult to conduct. The N-of-1 trial design offers a rigorous alternative for evaluating individualized treatment effects.

AIM

To map the extent, nature, and characteristics of N-of-1 trials in liver diseases and identify research gaps.

METHODS

We followed the Joanna Briggs Institute methodology for scoping reviews and PRISMA extension for Scoping Reviews reporting standards, using the Population, Concept, and Context framework. The Population comprised patients with chronic liver disease, the Concept was the use of an N-of-1 trial design, and the Context included clinical or health care settings worldwide, without geographic restriction. We searched MEDLINE (via Ovid), EMBASE, Scopus, and the Cochrane Library from inception through March 17, 2026. Two reviewers independently screened records in Covidence, with disagreements resolved by consensus. Eligible sources were English-language publications explicitly using an N-of-1 design in patients with liver diseases. Data charting captured study design, population, interventions, outcomes, and statistical methods. According to Joanna Briggs Institute guidance, a formal risk-of-bias assessment was not required; however, an optional narrative appraisal was performed.

RESULTS

Of 76 records identified, 2 empirical N-of-1 studies met the eligibility criteria. One evaluated oral thiamine in 3 patients with chronic hepatitis B and reported reduced aminotransferase levels and improved virological markers using t-tests. However, the pooled analysis of data from only 3 patients was statistically problematic and should not be considered strong evidence. The second study evaluated ursodeoxycholic acid in a patient with hepatic sarcoidosis over four crossover cycles and demonstrated improvement in cholestasis using a Wilcoxon test for paired data. The optional narrative appraisal found that both studies lacked randomization and blinding and did not use pre-specified protocols, raising concerns about internal validity.

CONCLUSION

No identified study used aggregated N-of-1 analyses, Bayesian methods, or frameworks for integrating N-of-1 evidence into clinical decision-making. N-of-1 trials remain markedly underused in hepatology despite the presence of rare, stable, chronic liver diseases for which traditional randomized controlled trials may be impractical. Broader adoption, supported by Bayesian analytical methods, electronic health record integration, and reporting aligned with the CONSORT extension specifically developed for N-of-1 trials, could advance personalized care and complement conventional trial designs in future hepatology research.

Keywords: N-of-1 trial; Liver Disease; Crossover design; Single-patient trials; Individualized treatment

Core Tip: Many rare, chronic, and stable liver diseases are difficult to investigate using conventional randomized controlled trials. N-of-1 trials are randomized, multiple-crossover trials designed to evaluate treatment effects in an individual patient. In this scoping review, we identified only two hepatology studies using this design: One evaluating thiamine in chronic hepatitis B and the other evaluating ursodeoxycholic acid in hepatic sarcoidosis. These findings highlight the underuse of N-of-1 trials as a potentially valuable approach for studying rare, chronic, and stable liver diseases.

Write to the Help Desk